Plain-English translation of NCT07444060 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing two biologic medications—guselkumab and ustekinumab—to see which one works better for people with Crohn's disease that causes narrowing (strictures) in the intestines. Both medications are designed to reduce inflammation in the digestive system. Researchers will follow participants over time and compare how well each medication relieves bowel obstruction symptoms and helps the intestines heal.
Crohn's disease can cause the intestines to narrow and become blocked, leading to severe pain and digestive problems that are hard to treat. This study aims to find out whether this medication can reduce stricturing complications and help avoid surgery.
You likely qualify if…
You likely don't qualify if…
You will take one of the two biologic medications as prescribed by your doctor, and your care team will monitor how you respond over time. You will have several follow-up visits where doctors will check your symptoms, perform blood and stool tests, do imaging scans and endoscopy as needed, and ask you about your pain and quality of life. The study will track your disease activity and whether the medication helps reduce bowel narrowing and obstruction symptoms.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
China